250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotechnology Startup Investors in United States in September 2025

A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotechnology startups based in United states. We rank investors based on the number of investments they made in Biotechnology companies from United states. We update this investor list every month.

Top 50 Biotechnology Startup Investors in United States in September 2025

Investor Biotechnology United States investments
SOSV 124
ARCH Venture Partners 114
Alexandria Venture Investments 92
OrbiMed 79
Atlas Venture 68
New Enterprise Associates 66
Versant Ventures 64
Innova Memphis 62
Third Rock Ventures 60
MPM Capital 60
5AM Ventures 60
Khosla Ventures 59
Polaris Partners 59
F-Prime 54
RA Capital Management 54
BioAdvance 49
Canaan Partners 49
Andreessen Horowitz 44
The Column Group 44
Novartis Venture Fund 43
KdT Ventures 42
Connecticut Innovations 41
DCVC 40
GV 40
Lux Capital 40
Fifty Years 40
Frazier Healthcare Partners 39
Hatteras Venture Partners 39
Sofinnova Investments 37
Alumni Ventures 36
Dolby Family Ventures 36
Pfizer Venture Investments 36
Mission BioCapital 35
Life Science Angels 35
Northpond Ventures 35
Boston Harbor Angels 34
Amgen Ventures 33
Domain Associates 33
Refactor 32
Novo Holdings 32
Founders Fund 32
Civilization Ventures 32
North Carolina Biotechnology Center 31
Omega Funds 31
Takeda Ventures 30
Flagship Pioneering 30
Vivo Capital 30
Eli Lilly 29
Alta Partners 29
Bay City Capital 29
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
SOSV VC Fund · Princeton, New Jersey, United States · 75 investments in the past 12 months
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Seed, Convertible Note, Pre-Seed
  • United States, India, United Kingdom
Portfolio highlights
  • MixRift — MIXRIFT - game developers specialized in Mixed Reality
  • unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
  • Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
ARCH Venture Partners VC Fund · Chicago, Illinois, United States · 16 investments in the past 12 months
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, United Kingdom
Portfolio highlights
  • Dispatch Bio — Dispatch Bio helps create a world where all cancer patients can be cured.
  • Atlas Data Storage — Atlas Data Storage develops data storage systems utilizing synthetic DNA to encode digital information. The company offers end-to-end solutions that integrate semiconductor-based synthesis and enzyme engineering to store data in DNA strands. This approach aims to provide long-term, high-density storage options for various sectors. Atlas DataStorage's technology is designed to address the growing demand for scalable and energy-efficient data storage solutions.
  • Kriya Therapeutics — Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
Alexandria Venture Investments VC Fund · Pasadena, California, United States · 28 investments in the past 12 months
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Canada, France
Portfolio highlights
  • Remedy Plan Therapeutics — Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
  • Dispatch Bio — Dispatch Bio helps create a world where all cancer patients can be cured.
  • GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
OrbiMed VC Fund · New York, New York, United States · 44 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
  • Treeline Biosciences — Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
  • Congruence Therapeutics — ABOUT US We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational chemistry. Our Science Traditional drug design is limited At Congruence,
Atlas Venture VC Fund · Cambridge, Massachusetts, United States · 9 investments in the past 12 months
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
  • Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
  • Vima Therapeutics — There are over 1 million people with dystonia and related movement disorders in the US and over 100,000 people with isolated dystonia.
New Enterprise Associates VC Fund · Menlo Park, California, United States · 51 investments in the past 12 months
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Series B, Series C
  • United States, India, Canada
Portfolio highlights
  • Aurelian — Aurelian is an AI platform designed to automate routes, triage, and resolve non-emergency police calls.
  • Mojo Vision — Mojo Vision is a developer of augmented reality products and platforms intended to invent the future of computing. The company has developed a smart contact lens with a built-in display that gives timely information without interrupting the focus and delivers immediate, powerful, and relevant information without the intrusions of today'smobile devices, enabling users to connect with others at a glance, anytime, anywhere handsfree.Mojo Vision was founded in 2015 and headquartered in Saratoga, California.
  • Strive Health — Strive Health is a built-for-purpose company working with innovative payors and providers to transform kidney care. Strive Health significantly improves patient outcomes and experience with a high-touch, technology-enabled clinical model that cares for chronic kidney disease patients across their entire healthcare journey, from primary care-levelengagement through dialysis. Strive was launched out of Oxeon’s Venture Studio and is backed by New Enterprise Associates, Town Hall Ventures, Echo Health Ventures, and Ascension Ventures.
Versant Ventures VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
  • Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
  • Kriya Therapeutics — Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
Innova Memphis VC Fund · Memphis, Tennessee, United States
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more
Investment focus
  • Health Care, Medical, Medical Device
  • Seed, Pre-Seed, Funding Round
  • United States, Argentina, United Kingdom
Portfolio highlights
  • HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
  • iYOTAH Solutions — Take your dairy operation to the next level. Our state of the art platform helps you save time, increase efficiencies and profits and unlock new opportunities.
  • Soiltech Wireless — Soiltech Wireless is a developer of ag-tech solutions to design electronic devices for agricultural professionals. Its product provides real-time data to drive efficiency and optimize quality. It also provides actionable data without installation hassles and creates scalable monitoring solutions for farmers.The company was founded in 2019 and isheadquartered in Rupert, Idaho.
Third Rock Ventures VC Fund · Boston, Massachusetts, United States · 2 investments in the past 12 months
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
  • Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
  • Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
MPM Capital VC Fund · Cambridge, Massachusetts, United States
Powering Breakthroughs in Life Sciences
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series A, Series B, Series C
  • United States, Canada, United Kingdom
Portfolio highlights
  • āshibio — āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course.
  • Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
  • Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.
5AM Ventures VC Fund · Menlo Park, California, United States · 6 investments in the past 12 months
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Fellow Health — Test sperm privately from home and get a doctor-reviewed male fertility report containing detailed semen analysis results.
  • Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
  • CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.
Khosla Ventures VC Fund · Menlo Park, California, United States · 88 investments in the past 12 months
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Series A, Series B, Seed
  • United States, India, United Kingdom
Portfolio highlights
  • Inkeep — inkeep provides conversational search for developer-focused companies. We use LLMs to understand a company’s docs, GitHub issues, Stack Overflow threads and more to answer developer questions and increase customer activation.
  • Aven — Inventing new ways to save people money
  • Cognition — Cognition is an applied artificial intelligence lab that focuses on reasoning and code.
Polaris Partners VC Fund · Boston, Massachusetts, United States · 6 investments in the past 12 months
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series B, Series A, Series C
  • United States, Ireland, Singapore
Portfolio highlights
  • FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
  • Leyden Labs — Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
  • Auron Therapeutics — A differentiated approach to cure cancer.
F-Prime VC Fund · Cambridge, Massachusetts, United States · 29 investments in the past 12 months
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • Apreo Health — Apreo Health is developer of medical apparatus designed for diagnosing or treating respiratory, pulmonary, and lung conditions.
  • Dataplor — Leveraging machine learning, AI, and human capital, dataplor delivers verified international places data to the world's leading companies.
  • Canary Technologies — Use Canary to securely conduct contactless check-in and process credit card authorizations, contracts, and amenities online. Canary is the only PCI Level-1 Compliant solution for hotel authorizations. Schedule a demo today, and see how we can help your properties reduce chargebacks, save time, and improve the guest experience.
RA Capital Management VC Fund · Boston, Massachusetts, United States · 43 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Post-IPO Equity
  • United States, United Kingdom, Canada
Portfolio highlights
  • Belite Bio — Belite Bio focused on first-in-class therapeutics targeting untreatable inherited orphan diseases and age-related metabolic diseases, including atrophic age-related macular degeneration, stargardt disease, and nonalcoholic steatohepatitis. They develop anti-RBP4 therapies to treat age-related metabolic diseases, including macular degeneration,liver disease, and diabetes. Their technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease, and diabetes.
  • Reframe Systems — Robotic microfactories for building net-zero homes 2x faster, 2x cheaper with 10x lower carbon
  • Alchemab Therapeutics — Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
BioAdvance VC Fund · Philadelphia, Pennsylvania, United States
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Funding Round, Series A
  • United States, Canada
Portfolio highlights
  • KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
  • Tolerance Bio — Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
  • Vittoria Biotherapeutics — Vittoria Biotherapeutics develops gene-edited cell therapies.  they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.
Canaan Partners VC Fund · Menlo Park, California, United States · 22 investments in the past 12 months
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
  • Software, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, United Kingdom, Israel
Portfolio highlights
  • Alkymi — Alkymi is an intelligent data processing and workflow automation solution designed to empower business users. We help free huge volumes of data from emails and documents to accelerate decision-making.
  • Field AI — Field AI develops autonomy software that equips mobile robots with a universal, risk-aware brain. It offers Field Foundation Models™ (FFMs) that enable embodiment-agnostic operation across legged, wheeled, flying, and tracked platforms. The company’s technology empowers robots to work safely in dynamic, unmapped environments, without reliance onGPS, pre-programmed routes, or maps, operating fully at the edge in real-time. Robots using this software can be deployed across industries such as construction, energy, mining, agriculture, urban operations, manufacturing, power and utilities, and federal applications, among others.
  • Journey Live — Journey is shifting the way modern companies prioritize mental health. Our proactive, inclusive tools engage every employee, every day.
Andreessen Horowitz VC Fund · Menlo Park, California, United States · 111 investments in the past 12 months
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
  • Software, Information Technology, Internet
  • Series A, Seed, Series B
  • United States, United Kingdom, Brazil
Portfolio highlights
  • Lead — Lead Bank is a community-minded, independent commercial bank with a national client base recognized for its imaginative approach to community banking.
  • Databricks — Databricks offers a unified platform for data, analytics and AI. Build better AI with a data-centric approach. Simplify ETL, data warehousing, governance and AI on the Data Intelligence Platform.
  • Allocate — Allocate is the operating system for private market alternatives investing
The Column Group VC Fund · San Francisco, California, United States · 5 investments in the past 12 months
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • A2 Biotherapeutics — A2 is dedicated to advancing cancer treatment through pioneering cell therapy. Our T cells target solid tumors with precision, transforming the future of medicine.
  • Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
  • Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 7 investments in the past 12 months
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
  • Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
  • Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
KdT Ventures VC Fund · Austin, Texas, United States · 4 investments in the past 12 months
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Israel, Germany
Portfolio highlights
  • Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
  • PHNX Materials — PHNX Materials is a manufacturing company that specializes in turning waste into essential materials and reduce carbon emissions.
  • Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Connecticut Innovations VC Fund · Rocky Hill, Connecticut, United States · 7 investments in the past 12 months
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Seed, Series A, Funding Round
  • United States, Israel, Canada
Portfolio highlights
  • Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
  • VeraDermics — VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
  • PHȲND — PHȲND is a subscription-free cloud gaming platform that offers a way to discover, play, and socialize across a wide variety of games.
DCVC VC Fund · San Francisco, California, United States · 19 investments in the past 12 months
We are deep tech venture capital.
Show more
Investment focus
  • Software, Artificial Intelligence, Machine Learning
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Halter — Halter creates GPS enabled, solar powered collars for cows. The collar hardware allows farmers to use simple tablet app software to remotely set geographic boundaries for cattle, virtual fences. Farmers use Halter's system to avoid physically herding cows, maximizing farmer time and productivity.
  • Insight M — Insight M develops aerial monitoring technology for methane detection for the energy industry. It supports physical science expertise with data analytics to survey large areas, create digital maps in optical and infrared wavelengths, and scan various pipelines and acres of territory to identify major sources of gas loss.The company completed thefirst-ever basin-wide aerial survey for methane detection in its 2019 survey of the Permian Basin. Kairos Aerospace’s mission is to improve operational excellence for the oil and gas industry with cost-effective, efficient methane reductions at scale.
  • Chai Discovery — Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules.
GV VC Fund · Mountain View, California, United States · 47 investments in the past 12 months
GV supports innovative founders moving the world forward.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • Intent Inc — GroupUltra is a platform that allows users to program their groups and design their communities.
  • Phoebe — Phoebe is an agentic search tool for tech stack data. It helps engineering teams to troubleshoot many sorts of problems much faster, from minor bugs to major incidents. Phoebe can also initiate searches proactively to help anticipate and triage new issues.
  • Blue Water Autonomy — Blue Water Autonomy develops fully autonomous, unmanned ships designed from the keel up for long-endurance missions. Its vessels, about 100 feet and 100 tons, are purpose-built for open-ocean operations with modular payloads for logistics, surveillance, or munitions. The ships integrate hardware, software, and AI systems to operate independentlyover long durations. They are engineered for mass producibility, using medium-sized shipyards to keep production simpler and more cost-effective than traditional crewed ships. While initially focused on defense applications, the company also targets future use in commercial sectors such as cargo shipping, offshore energy, and other demanding maritime operations.
Lux Capital VC Fund · New York, New York, United States · 40 investments in the past 12 months
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Series A, Seed, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • Armada — The Armada Platform is a whole new way to succeed at the Edge with Starlink connectivity, mobile data centers & AI. Schedule a demo today.
  • Hadrian — We are building the planet's most efficient factory to accelerate a democratic, abundant, spacefaring future.
  • Basic Capital — Stand out with the only 401(k) that gives your employees more capital to invest and build wealth.
Fifty Years VC Fund · San Francisco, California, United States · 2 investments in the past 12 months
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Germany, Canada
Portfolio highlights
  • Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
  • Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
  • Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
Frazier Healthcare Partners VC Fund · Seattle, Washington, United States
With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Post-IPO Equity
  • United States, Canada, Ireland
Portfolio highlights
  • Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
  • New Amsterdam Pharma — We're advancing a new era of treatment for cardiovascular disease and other lipid-related conditions.
  • Day One Biopharmaceuticals — Discover how Day One is disrupting the status quo of traditional drug development to bring new medicines to children and adults with cancer.
Hatteras Venture Partners VC Fund · Durham, North Carolina, United States · 7 investments in the past 12 months
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Canada
Portfolio highlights
  • HistoSonics — HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
  • Atsena Therapeutics — Atsena is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
  • GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
Sofinnova Investments VC Fund · Menlo Park, California, United States · 3 investments in the past 12 months
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, France, Switzerland
Portfolio highlights
  • Axonis Therapeutics — AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
  • Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
  • Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
Alumni Ventures VC Fund · Manchester, New Hampshire, United States · 80 investments in the past 12 months
Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC.It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor withexpertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography.Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.
Show more
Investment focus
  • Software, Information Technology, Artificial Intelligence
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Kognitos — Kognitos is in stealth mode.
  • CRED — Compare millions of commercial data points and uncover unique and personalised opportunities for your brand.
  • Spekter Games — Spekter Games offers well-tested free-to-play Web2 mobile games that have been improved with a skillfully designed Web3 incentive layer, as well as chat-based super apps.
Dolby Family Ventures VC Fund · San Francisco, California, United States · 5 investments in the past 12 months
Investing in early-stage companies solving the biggest science and engineering challenges since 2014.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Seed, Series B
  • United States, Austria, Switzerland
Portfolio highlights
  • Magnefy — Optimize your transformer monitoring with our innovative predictive maintenance solutions using AI & advanced magnetic sensor technology.
  • Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
  • Esper Satellite Imagery — Esper is building and launching the world's most versatile satellite imagery network for mineral exploration, agronomy, and national security. Order imagery now.
Pfizer Venture Investments VC Fund · New York, New York, United States · 4 investments in the past 12 months
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • TRex Bio — TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
  • Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
  • TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
Mission BioCapital VC Fund · Cambridge, Massachusetts, United States · 13 investments in the past 12 months
Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Funding Round, Series B
  • United States, Germany, Switzerland
Portfolio highlights
  • D2B3 — The future of treating brain diseases.
  • Alessa Therapeutics — Alessa Therapeutics is a pre-clinical stage company that develops localized treatments for solid organ disease.
  • SiteOne Therapeutics — SiteOne develops selective inhibitors of sodium channels as non-opioid treatments to address acute and chronic pain
Life Science Angels VC Fund · Sunnyvale, California, United States
Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Funding Round, Seed, Series A
  • United States, Israel, The Netherlands
Portfolio highlights
  • Neurava — Neurava has developed wearable diagnostics for epilepsy patients including those at risk of SUDEP. The company specializes in the fields of medical device manufacturing, healthcare, and health diagnostics.
  • Flyte — Flyte promotes cellular healing in pelvic floor muscles for lasting results. Flyte is fast, proven, safe, pelvic floor therapy for bladder control.
  • Trio Pharmaceuticals — Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California.
Northpond Ventures VC Fund · Bethesda, Maryland, United States · 2 investments in the past 12 months
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
  • VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
  • Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Boston Harbor Angels VC Fund · Boston, Massachusetts, United States
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.
Show more
Investment focus
  • Biotechnology, Health Care, Medical Device
  • Angel, Seed, Series A
  • United States, Canada, India
Portfolio highlights
  • Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
  • Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
  • Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Amgen Ventures VC Fund · San Francisco, California, United States
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Canada, United Kingdom
Portfolio highlights
  • Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
  • Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.
  • Mindset Medical — Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona.
Domain Associates VC Fund · San Diego, California, United States
INVESTMENT ADVISORS TO THE FIRST VC FUND DEDICATED TO BIOTECH INVESTMENT MANAGER OF 9 SUBSEQUENT BIOTECH VC FUNDS
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series C, Series A
  • United States, Canada, Estonia
Portfolio highlights
  • Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
  • Antios Therapeutics — This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
  • Fractyl Health — Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Refactor VC Fund · Burlingame, California, United States · 6 investments in the past 12 months
Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Seed, Series A, Series B
  • United States, United Kingdom, New Zealand
Portfolio highlights
  • Pilgrim — Pioneering a biologically enhanced future for humanity.
  • Causal Labs — Causal Labs provides AI physics models to predict and control the weather.
  • Remedy Scientific — Remedy decontaminates land with scalable, AI-driven systems, advanced chemistry and precise sensors, restoring sites to their full productive potential.
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 22 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • Mission Bio — We offer the only multi-omics single-cell technology solution that simultaneously detects SNV, CNV, and protein data from the same cell. Find out more.
  • Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
  • Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.
Founders Fund VC Fund · San Francisco, California, United States · 33 investments in the past 12 months
Founders Fund is a San Francisco based venture capital firm investing in companies building revolutionary technologies.
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Series A, Seed, Series B
  • United States, United Kingdom, Germany
Portfolio highlights
  • Armada — The Armada Platform is a whole new way to succeed at the Edge with Starlink connectivity, mobile data centers & AI. Schedule a demo today.
  • Eight Sleep — Fall asleep faster and stay asleep longer with personalized cooling and heating for each side of the bed. The Pod reduces snoring, tracks your sleep, and works with any mattress. Try it risk-free for 30 nights.
  • Aven — Inventing new ways to save people money
Civilization Ventures VC Fund · San Francisco, California, United States · 2 investments in the past 12 months
DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, United Kingdom, Brazil
Portfolio highlights
  • Antheia — Transforming pharmaceutical supply chains using synthetic biology, to end drug shortages and unlock new opportunities in development and discovery
  • SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
  • Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.
North Carolina Biotechnology Center VC Fund · Alexander, North Carolina, United States
The North Carolina Biotechnology Center is a private, non-profit corporation funded by the N.C. General Assembly to strengthen biotechnology research, business and education statewide. The Center is not a site for laboratory research; it works to support job creation in the biotechnology industry.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Debt Financing, Grant, Funding Round
  • United States, United Kingdom
Portfolio highlights
  • Phase — Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
  • QATCH Technologies — Get the most out of a drop
  • Atlantic Fish Company — Atlantic Fish Co is a cultivated seafood company using cellular agriculture to bring the world sustainable delicious seafood.
Omega Funds VC Fund · Boston, Massachusetts, United States · 7 investments in the past 12 months
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
  • Alleviant Medical — Interventional therapy for congestive heart failure
  • Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Takeda Ventures VC Fund · San Diego, California, United States · 3 investments in the past 12 months
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
  • Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
  • EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.
Flagship Pioneering VC Fund · Cambridge, Massachusetts, United States · 8 investments in the past 12 months
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series C, Series A
  • United States, Canada, United Kingdom
Portfolio highlights
  • Etiome — Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines.
  • Lila Sciences — Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation.
  • Terrana Biosciences — Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions.
Vivo Capital VC Fund · Palo Alto, California, United States · 6 investments in the past 12 months
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series C, Post-IPO Equity
  • United States, China, United Kingdom
Portfolio highlights
  • CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.
  • Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
  • Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.
Eli Lilly VC Fund · Indianapolis, Indiana, United States · 24 investments in the past 12 months
Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Funding Round
  • United States, United Kingdom, Canada
Portfolio highlights
  • Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
  • Signify Bio — Signify Bio combines the promise of signal peptide engineered control with the speed and power of mRNA encoded design.
  • Stylus Medicine — Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
Alta Partners VC Fund · San Francisco, California, United States · 3 investments in the past 12 months
Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • EGenesis — At eGenesis, we envision a world in which no one dies waiting for an organ transplant.
  • Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
  • Harbor Health — Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas.
Bay City Capital VC Fund · San Francisco, California, United States
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition andagribusiness sector fund.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, Canada, Denmark
Portfolio highlights
  • Oculis — Experience the Future of Eye Care: Oculis, a Clinical Biopharmaceutical Innovator, Pioneering Breakthrough Treatments for Ophthalmic Diseases & Transforming Lives Globally.
  • Bridge Medicines — MEET BRIDGE MEDICINES Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the
  • Sembiosys Genetics — SemBioSys Genetics Inc., a Canadian biotechnology company, announced today that it has signed a feasibility agreement with Dow AgroSciences LLC, of Indianapolis, Indiana, for the Stratosome(TM) Biologics System and its application to animal health biologics. Under the terms of the agreement, SemBioSys and Dow AgroSciences will engage incollaborative research with the aim of determining if the Stratosome(TM) Biologics System can enable the commercialisation of a Dow AgroSciences plant-made vaccine. Under the terms of the agreement, SemBioSys will receive upfront and milestone payments. Further terms of the agreement were not disclosed. "We believe that our Stratosome(TM) Biologics System, with its economic and functional benefits, makes it an outstanding platform for animal health products. We are extremely pleased to be working with Dow AgroSciences in developing their vaccine," said Andrew Baum, president and CEO of SemBioSys."We are very pleased to be working with SemBioSys in evaluating the Stratosome(TM) technology and its application to plant-made biologics for the animal health industry," stated Butch Mercer, Global Business Leader, Animal Health and Nutrition for Dow AgroSciencesThis is the third funded development agreement announced by SemBioSys in the last six months. In December, SemBioSys announced that it had executed a development agreement with Martek Biosciences Corporation (Nasdaq: MATK) to co- develop value-added specialty oil products (DHA containing safflower oil) with potential pharmaceutical and nutraceutical applications. In February, SemBioSys announced that it had entered into an agreement with Syngenta for access to SemBioSys' proprietary oilbody based Stratosome(TM) Biologics and StratoCapture(TM) Purification Systems for the development of Syngenta's biologic products.About SemBioSys Genetics Inc. (www.sembiosys.com)Calgary, Alberta-based SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development of therapeutic proteins and oils using its proprietary oilbody-based technology - the Stratosome(TM) Biologics System. Spun out of the University of Calgary in 1994, the company's investors include Bay City Capital, Dow AgroSciences Canada, Inc., Ventures West Management Inc., BDC Venture Capital, University Technologies International Inc., RBC Capital Partners and Maurice Moloney Ph.D. scientific founder and chief scientific officer. In addition to these investors, SemBioSys has received repayable contributions of CAD$5.5MM from Technology Partnerships Canada, an agency of Industry Canada, and CAD$4.9MM from AVAC Ltd. SemBioSys has partnerships with Syngenta Participations AG and Martek Biosciences for the use of its Stratosome(TM) technology for the development of therapeutic products.
Investors by industry
Investors by country
Investors in United States by industry